{"disease":{"id":"overactive-bladder","name":"Overactive bladder","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":5},"drugs":{"marketed":[{"drug_id":"onabotulinumtoxina","indication_name":"Overactive Bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Botox","generic_name":"ONABOTULINUMTOXINA","company_name":"Allergan","drug_phase":"marketed","molecular_target":"SNAP-25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":60,"revenue":"5300","mechanism":"BOTOX blocks neuromuscular transmission by inhibiting acetylcholine release through cleavage of SNAP-25."},{"drug_id":"toviaz","indication_name":"Overactive Bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Toviaz","generic_name":"Fesoterodine Fumarate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M2","drug_class":"fesoterodine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"solifenacin-succinate","indication_name":"Overactive Bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SOLIFENACIN SUCCINATE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic receptors","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Solifenacin blocks muscarinic receptors, reducing urinary bladder smooth muscle contractions."},{"drug_id":"darifenacin-hydrobromide","indication_name":"Overactive Bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DARIFENACIN HYDROBROMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"botulinum-toxin-type-a","indication_name":"Overactive bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuceiva","generic_name":"BOTULINUM TOXIN TYPE A","company_name":"GlaxoSmithKline K.K.","drug_phase":"marketed","molecular_target":"Synaptosomal-associated protein 25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":"Nuceiva works by blocking the release of acetylcholine, a neurotransmitter that transmits signals from nerve cells to muscles, thereby reducing muscle spasms and contractions."}],"pipeline":[{"drug_id":"torsemide","indication_name":"Heart failure with overactive bladder","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TORSEMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/K+/2Cl- carrier system","drug_class":"Loop Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Torsemide inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water."}],"offLabel":[],"totalMarketed":5,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03903094","title":"A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden","phase":"","overall_status":"COMPLETED","enrollment_count":6295279,"lead_sponsor_name":"Astellas Pharma Singapore Pte. Ltd.","has_results":false},{"nct_id":"NCT03602508","title":"Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania","phase":"","overall_status":"COMPLETED","enrollment_count":5589,"lead_sponsor_name":"Astellas Pharma Singapore Pte. Ltd.","has_results":false},{"nct_id":"NCT01972841","title":"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3527,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT01936870","title":"Drug Use Investigation for Toviaz","phase":"","overall_status":"COMPLETED","enrollment_count":2521,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05652023","title":"Noninvasive Ultrasound Assessment of Detrusor Dysfunction","phase":"","overall_status":"RECRUITING","enrollment_count":2023,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03536494","title":"Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron","phase":"NA","overall_status":"COMPLETED","enrollment_count":1932,"lead_sponsor_name":"Catalan Institute of Health","has_results":false},{"nct_id":"NCT01638000","title":"A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1887,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":true},{"nct_id":"NCT02045862","title":"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1829,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT03492281","title":"A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1530,"lead_sponsor_name":"Urovant Sciences GmbH","has_results":true},{"nct_id":"NCT02386072","title":"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)","phase":"","overall_status":"COMPLETED","enrollment_count":1524,"lead_sponsor_name":"Astellas Scientific & Medical Affairs, Inc.","has_results":false},{"nct_id":"NCT03594058","title":"A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1413,"lead_sponsor_name":"Velicept Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03902080","title":"Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1105,"lead_sponsor_name":"Urovant Sciences GmbH","has_results":true},{"nct_id":"NCT07044778","title":"Prevalence And Risk Factors of Overactive Bladder Syndrome Among Egyptian Medical Students, and Their Impact On Health-Related Quality Of Life","phase":"","overall_status":"COMPLETED","enrollment_count":1003,"lead_sponsor_name":"Zagazig University","has_results":false},{"nct_id":"NCT07371000","title":"Early Detection of OAB and Elimination of Negative Impact on Quality of Life","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Institute of Health Information and Statistics of the Czech Republic","has_results":false},{"nct_id":"NCT02216214","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":888,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT02320773","title":"A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":863,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":false},{"nct_id":"NCT04534491","title":"Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":855,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT00915525","title":"Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":829,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT03801239","title":"Reliability of Polish-Version Overactive Bladder Syndrom Scores (OABSS)","phase":"","overall_status":"COMPLETED","enrollment_count":822,"lead_sponsor_name":"Medical University of Lublin","has_results":false},{"nct_id":"NCT03572231","title":"A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China","phase":"","overall_status":"COMPLETED","enrollment_count":805,"lead_sponsor_name":"Astellas Pharma Singapore Pte. Ltd.","has_results":false},{"nct_id":"NCT07494864","title":"Effects of Microbiological and Immunological Factors on the Lower Urinary Tract","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT02757768","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":715,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT02294396","title":"Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":649,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT05282069","title":"A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":607,"lead_sponsor_name":"Dong-A ST Co., Ltd.","has_results":false},{"nct_id":"NCT05452434","title":"Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03044912","title":"Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":574,"lead_sponsor_name":"Buddhist Tzu Chi General Hospital","has_results":false},{"nct_id":"NCT02656173","title":"A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":568,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT01093534","title":"Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":547,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT03583372","title":"An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":506,"lead_sponsor_name":"Urovant Sciences GmbH","has_results":true},{"nct_id":"NCT05040984","title":"Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Far Eastern Memorial Hospital","has_results":false},{"nct_id":"NCT07205445","title":"Tensi+ European Registry","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Stimuli Technology","has_results":false},{"nct_id":"NCT07357714","title":"Urinary Function and Multimorbidity Risks: A Longitudinal Study in Beijing Community-Dwelling Elderly","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT04429360","title":"What is the Effect of Prolapse Surgery on Voiding?","phase":"","overall_status":"UNKNOWN","enrollment_count":453,"lead_sponsor_name":"Universiteit Antwerpen","has_results":false},{"nct_id":"NCT03475706","title":"Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":438,"lead_sponsor_name":"Velicept Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05067478","title":"Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)","phase":"","overall_status":"COMPLETED","enrollment_count":403,"lead_sponsor_name":"Urovant Sciences GmbH","has_results":false},{"nct_id":"NCT04693897","title":"Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT00876447","title":"A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":397,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT03320850","title":"BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":383,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT05512039","title":"Reduced-dose Botox for Urgency Incontinence Among Elder Females","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":376,"lead_sponsor_name":"Dartmouth-Hitchcock Medical Center","has_results":false},{"nct_id":"NCT02138747","title":"A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":376,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT01767519","title":"A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":356,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT03486639","title":"Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity","phase":"","overall_status":"UNKNOWN","enrollment_count":330,"lead_sponsor_name":"Assaf-Harofeh Medical Center","has_results":false},{"nct_id":"NCT07305298","title":"Mirabegron in Patients With Age-Related Macular Degeneration","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":312,"lead_sponsor_name":"University of Naples","has_results":false},{"nct_id":"NCT03566134","title":"A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":306,"lead_sponsor_name":"Dong-A ST Co., Ltd.","has_results":false},{"nct_id":"NCT05709990","title":"Efficacy and Safety of High Dose Vitamin D Supplementation for Overactive Bladder Dry in Children","phase":"NA","overall_status":"COMPLETED","enrollment_count":303,"lead_sponsor_name":"Xing Liu","has_results":false},{"nct_id":"NCT05200923","title":"Pelvic Health Electrically Evoked Recording (PEER) 2 Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"MedtronicNeuro","has_results":false},{"nct_id":"NCT01898624","title":"Specified Drug Use-results Survey of Betanis Tablets","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT03575702","title":"Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"R-Pharm","has_results":true},{"nct_id":"NCT06184334","title":"Management of OAB in Female Patients .","phase":"NA","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Elsayed Abdelhalim Elsayed","has_results":false},{"nct_id":"NCT03596671","title":"BlueWind RENOVA iStim™ System for the Treatment of OAB","phase":"NA","overall_status":"COMPLETED","enrollment_count":282,"lead_sponsor_name":"BlueWind Medical","has_results":true}],"total":50},"guidelines":[{"drug_id":"toviaz","guideline_body":"FDA label","recommendation":"Fesoterodine fumarate extended-release tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}